Nilotinib effects in Parkinson's disease and dementia with lewy bodies

Journal of Parkinson's Disease

Volumn 6, Issue 3, 2016, Pages 503-517

  Pagan, Fernando ^b   Hebron, Michaeline ^a   Valadez, Ellen H ^b   Torres Yaghi, Yasar ^b   Huang, Xu ^a   Mills, Reversa R ^b   Wilmarth, Barbara M ^b   Howard, Hellen ^b   Dunn, Connell ^b   Carlson, Alexis ^b   Lawler, Abigail ^b   Rogers, Sean L ^b   Falconer, Ramsey A ^b   Ahn, Jaeil ^a   Li, Zhaoxia ^b   Moussa, Charbel ^a,b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

dopamine; homovanillic acid; Lewy bodies; Nilotinib; Parkinson; synuclein; tau

Indexed keywords

ABELSON KINASE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; DJ 1 PROTEIN; DOPAMINE; HOMOVANILLIC ACID; NILOTINIB; RASAGILINE; SELEGILINE; TAU PROTEIN; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; PYRIMIDINE DERIVATIVE;

AGED; ANXIETY DISORDER; ARTICLE; BACKACHE; BLOOD BRAIN BARRIER; BLURRED VISION; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COGNITION ASSESSMENT; COMMON COLD; CONFUSION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIFFUSE LEWY BODY DISEASE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; DYSGRAPHIA; ECZEMA; FATIGUE; FEMALE; FOOT DISEASE; GINGIVA DISEASE; HALLUCINATION; HEADACHE; HUMAN; INCONTINENCE; MALE; MAXIMUM PLASMA CONCENTRATION; MOTOR PERFORMANCE; NAUSEA; OUTCOME ASSESSMENT; PARANOIA; PARKINSON DISEASE; PATHOLOGICAL CRYING; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; SKIN IRRITATION; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINARY URGENCY; VERY ELDERLY; WEAKNESS; COMPLICATION; DEMENTIA; FOLLOW UP; LEWY BODY DISEASE;

DEMENTIA; FOLLOW-UP STUDIES; HUMANS; LEWY BODY DISEASE; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; PYRIMIDINES;

EID: 84983738240     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-160867     Document Type: Article

References (48)

1. Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, & NixonRA(2008) Autophagy induction and autophagosome clearance in neurons: Relationship to autophagic pathology in Alzheimer's disease. J Neurosci, 28, 6926-6937.
2. Kegel KB, Kim M, Sapp E, McIntyre C, Castano JG, Aronin N, &DiFigliaM(2000) Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J Neurosci, 20, 7268-7278.
3. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, & Cuervo AM (2005) Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. J Neuropathol Exp Neurol, 64, 113-122.
4. Ravikumar B, Duden R, & Rubinsztein DC (2002) Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet, 11, 1107-1117.
5. SabatiniDM(2006) mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer, 6, 729-734.
6. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, & Greene LA (2001) Expression of A53T mutant but not wild-type alphasynuclein in PC12 cells induces alterations of the ubiquitindependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci, 21, 9549-9560.
7. Webb JL, Ravikumar B, Atkins J, Skepper JN, & Rubinsztein DC (2003) Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem, 278, 25009-25013.
8. Nixon RA (2013) The role of autophagy in neurodegenerative disease. Nat Med, 19, 983-997.
9. Deremer DL, Ustun C, & Natarajan K (2008) Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther, 30, 1956-1975.
10. Skorski T (2011) BCR-ABL1 kinase: Hunting an elusive target with new weapons. Chem Biol, 18, 1352-1353.
11. Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, Belanger C, Manley PW, Leroy C, Etienne G, Roche S, & Pasquet JM (2008) Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res, 68, 9809-9816.
12. Salomoni P, & Calabretta B (2009) Targeted therapies and autophagy: New insights from chronic myeloid leukemia. Autophagy, 5, 1050-1051.
13. Hebron ML, Lonskaya I, & Moussa CE (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models. Hum Mol Genet, 22, 3315-3328.
14. Lonskaya I, Hebron ML, Desforges NM, Franjie A, & Moussa CE (2013) Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance. EMBO Mol Med, 5, 1247-1262.
15. Hebron ML, Lonskaya I, Sharpe K, Weerasinghe PP, Algarzae NK, Shekoyan AR, & Moussa CE (2013) Parkin ubiquitinates Tar-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6). J Biol Chem, 288, 4103-4115.
16. Hebron ML, Lonskaya I, Olopade P, Selby ST, Pagan F, & Moussa CE (2014) Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in alpha-Synucleinopathy. J Clin Cell Immunol, 5, 259.
17. Lonskaya I, Hebron M, Desforges NM, Schachter JB, & Moussa CE (2014) Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. J Mol Med, 92, 373-386.
18. Lonskaya I, Desforges NM, Hebron ML, & Moussa CE (2013) Ubiquitination increases parkin activity to promote autophagic alpha-synuclein clearance. PLoS One, 8, e83914.
19. Lonskaya I, Hebron ML, Desforges NM, Schachter JB, & Moussa CE (2014) Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. J Mol Med (Berl), 92, 373-386.
20. Lonskaya I, Hebron M, Chen W, Schachter J, & Moussa C (2014) Tau deletion impairs intracellular beta-Amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models. Mol Neurodegener, 9, 46.
21. Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, &Ko HS (2014) The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. Sci Rep, 4, 4874.
22. Mahul-Mellier AL, Fauvet B, Gysbers A, Dikiy I, Oueslati A, Georgeon S, Lamontanara AJ, Bisquertt A, Eliezer D, Masliah E, Halliday G, Hantschel O, & Lashuel HA (2014) c-Abl phosphorylates alpha-synuclein and regulates its degradation: Implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. Hum Mol Genet, 23, 2858-2879.
23. Ko HS, Lee Y, Shin JH, Karuppagounder SS, Gadad BS, Koleske AJ, Pletnikova O, Troncoso JC, Dawson VL, & Dawson TM (2010) Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc Natl Acad Sci U S A, 107, 16691-16696.
24. Imam SZ, Zhou Q, Yamamoto A, Valente AJ, Ali SF, Bains M, Roberts JL, Kahle PJ, Clark RA, & Li S (2011) Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: Implications for Parkinson's disease. J Neurosci, 31, 157-163.
25. Lev N, Ickowicz D, Melamed E, & Offen D (2008) Oxidative insults induce DJ-1 upregulation and redistribution: Implications for neuroprotection. Neurotoxicology, 29, 397-405.
26. Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, & Ariga H (2004) DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep, 5, 213-218.
27. Wang JY (2014) The capable ABL: What is its biological function? Mol Cell Biol, 34, 1188-1197.
28. Petzold A, Groves M, Leis AA, Scaravilli F, & Stokic DS (2010) Neuronal and glial cerebrospinal fluid protein biomarkers are elevated after West Nile virus infection. Muscle Nerve, 41, 42-49.
29. Petzold A, Michel P, Stock M, &SchluepM(2008) Glial and axonal body fluid biomarkers are related to infarct volume, severity, and outcome. J Stroke Cerebrovasc Dis, 17, 196-203.
30. Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, Levine SR, & Group Nr-PSS (2006) Association of serial biochemical markers with acute ischemic stroke: The National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke, 37, 2508-2513.
31. Persson L, Hardemark HG, Gustafsson J, Rundstrom G, Mendel-Hartvig I, Esscher T, & Pahlman S (1987) S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: Markers of cell damage in human central nervous system. Stroke, 18, 911-918.
32. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, & Schlossmacher MG (2011) alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with Parkinsonism: A cohort study. Lancet Neurol, 10, 230-240.
33. Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, & El-Agnaf O (2011) Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord, 26, 1428-1435.
34. Tateno F, Sakakibara R, Kawai T, Kishi M, & Murano T (2012) Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord, 26, 213-216.
35. Bakhsheshian J, Wei BR, Chang KE, Shukla S, Ambudkar SV, Simpson RM, Gottesman MM, & Hall MD (2013) Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2. Proc Natl Acad Sci U S A, 110, 20801-20806.
36. Zubenko GS, Marquis JK, Volicer L, Direnfeld LK, Langlais PJ, & Nixon RA (1986) Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: A correlative study. Biol Psychiatry, 21, 1365-1381.
37. Goldstein DS, Holmes C, &SharabiY(2012) Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. Brain, 135, 1900-1913.
38. Ren Y, Jiang H, Ma D, Nakaso K, & Feng J (2011) Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases. Hum Mol Genet, 20, 1074-1083.
39. Mollenhauer B, Trautmann E, Otte B, Ng J, Spreer A, Lange P, Sixel-Doring F, Hakimi M, Vonsattel JP, Nussbaum R, Trenkwalder C, & Schlossmacher MG (2012) alpha-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J Neural Transm, 119, 739-746.
40. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ, El-Agnaf OM, & Schlossmacher MG (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol, 213, 315-325.
41. Mollenhauer B, Trautmann E, Taylor P, Manninger P, Sixel-Doring F, Ebentheuer J, Trenkwalder C, & Schlossmacher MG (2013) Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett, 532, 44-48.
42. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, & Zhang J (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain, 133, 713-726.
43. Ohrfelt A, Grognet P, Andreasen N,Wallin A,Vanmechelen E, Blennow K, & Zetterberg H (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-A marker of synapse loss? Neurosci Lett, 450, 332-335.
44. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, & Ikeuchi T (2010) Differential levels of alpha-synuclein, beta-Amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry, 81, 608-610.
45. Lleo A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK, Andreasen N, Ghidoni R, Lewczuk P, Jeromin A, Winblad B, Tsolaki M, Mroczko B, Visser PJ, Santana I, Svenningsson P, Blennow K, Aarsland D, Molinuevo JL, Zetterberg H, & Mollenhauer B (2015) Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol, 11, 41-55.
46. Mollenhauer B, Bibl M, Wiltfang J, Steinacker P, Ciesielczyk B, Neubert K, Trenkwalder C, & Otto M (2006) Total tau protein, phosphorylated tau (181p) protein, betaamyloid( 1-42), and beta-Amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewybodies. Clin Chem Lab Med, 44, 192-195.
47. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, &Calabresi P (2008) Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry, 64, 850-855.
48. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligorska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, ShawLM, &Parkinson's Progression Markers I (2013) Association of cerebrospinal fluid beta-Amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol, 70, 1277-1287.